ecancer is a charity with a mission to raise the standards of care for cancer patients across the world through education. #openaccess

England
Joined February 2009
ecancer presents a free live interactive webinar on the latest in #bladdercancer on 16 November 17:00 GMT/18:00 CET. Register here for expert analysis 👉ecancer.org/bladder #ESMO26 #EMUC2026 #EMUC26 @AlisonBirtle @nachoduranm @amerseburger @MRoupret
4
2
408
Our newly published work in @ecancer! 🌍 Together with @assoGFAOP, we implemented a structured health-system assessment/improvement framework across pediatric oncology centers in Francophone Africa, identifying priorities & building a path to action.🎗️ ecancer.org/en/journal/artic…
1
3
255
Hot off the press! Quality indicators of pathology and laboratory medicine in cancer: a narrative synthesis of published literature - ecancer #ecancer @ecancer ecancer.org/en/journal/artic…
1
3
2
14
2,118
ecancer retweeted
Join the free ecancer live interactive webinar on telepathology in breast cancer care in LMICs 12:00 BST / 11:00 UTC 25th September. Part of the Grand Rounds in Breast Cancer series. Register👉 ecancer.org/telepathology #BreastCancer #oncology
1
375
🚀 Opening #IUCS26 | More than a meeting a growing global GU oncology community One of the things that struck me most from the opening session was the clarity of the vision behind IUCS: to build a truly international, multidisciplinary community around better care for patients with GU cancers. With the creation of IUCS CIC, that vision now has a formal non-profit structure focused on: ⚪ multidisciplinary care ⚪ translational and investigator-led research ⚪ evidence-based innovation ⚪ education and global collaboration ⚪ connecting science with everyday clinical practice What makes this especially meaningful is the diversity of perspectives brought together across countries, specialties and healthcare systems — all around one shared goal: better outcomes for our patients. A great way to begin two days of science, discussion and collaboration in Guildford. With leadership and contributions from @gbanna74 @ravikanesvaran @PasRescigno @alison_tree @amg120395 @ManiamAkash @neerajaiims @montypal @PGrivasMDPhD @ParamMariappan @DrYukselUrun @dmukherji @MicheleMaffezz @yekeduz_emre and the wider #IUCS26 faculty. @myESMO @ASCO @ASCOPost @AmerUrological @urotoday @UrologyTimes @OncLive @ecancer @Uroweb #GUOncology #UroOnc #ClinicalResearch #MedicalEducation #GlobalOncology
🚀 Opening #IUCS26 | From a meeting to a global GU oncology community The opening session highlighted the vision behind IUCS and the creation of IUCS CIC, a non-profit Community Interest Company dedicated to advancing multidisciplinary care, translational research and clinical education across genitourinary cancers. ⚪ Building an international and multidisciplinary GU oncology community ⚪ Accelerating evidence-based innovation ⚪ Connecting translational research with everyday clinical practice ⚪ Strengthening education, collaboration and investigator-led research ⚪ Bringing together expertise across countries and healthcare systems ⚪ Keeping the ultimate goal clear: better outcomes for our patients Great to see the community gathered in Guildford and ready for two days of science, discussion and collaboration. With leadership and contributions from @gbanna74 @ravikanesvaran @PasRescigno @alison_tree @amg120395 @ManiamAkash @neerajaiims @montypal @PGrivasMDPhD @ParamMariappan @DrYukselUrun @dmukherji @nataliagandur @MicheleMaffezz @yekeduz_emre and the wider #IUCS26 faculty. @myESMO @ASCO @ASCOPost @AmerUrological @urotoday @UrologyTimes @OncLive @ecancer @Uroweb #GUOncology #UroOnc #ClinicalResearch #MedicalEducation #GlobalOncology
6
1
13
1,715
At #ESMOGI26, @CentralParkWMD discusses GLEAM results. Zolbetuximab plus gemcitabine and nab-paclitaxel did not improve survival in CLDN18.2-positive MPC, highlighting the need for better patient selection and combination strategies. Watch the video👉bit.ly/3UyJiN6
1
4
552
At #ESMOGI26, @TaberneroJosep discusses that adagrasib plus cetuximab achieved higher response rates, including more CRs, in previously treated KRAS G12C-mutated mCRC, but did not significantly improve PFS or OS vs chemotherapy. Watch the interview👉bit.ly/4qxthTJ
1
1
492
At #ESMOGI26, Dr Michele Milella (@UniVerona) discusses targeted intratumoural phosphorus-32 microparticles plus FOLFIRINOX in uLAPC, showing encouraging local disease control and supporting further study of this combined approach. Watch the interview👉bit.ly/4gPfULa
297
At #ESMOGI26, Dr Nilo Azad (@hopkinskimmel) discusses early phase 1 results of dual RAS inhibition with zoldonrasib plus daraxonrasib in heavily pretreated KRAS G12D-mutated metastatic pancreatic cancer, showing encouraging activity. Watch interview👉bit.ly/3S6hM94
399
At #EHA2026, Prof Martin Schrappe (@UKSH_KI_HL) discusses that blinatumomab improved 4-year EFS to 83% vs 70% with intensive chemotherapy in high-risk paediatric B-ALL, while reducing relapse and severe treatment-related toxicities. Watch the interview👉bit.ly/3U8C56h
234
At #EHA2026, Prof Umberto Vitolo (@fprc_candiolo) discusses phase 3 frontMIND results showing tafasitamab plus lenalidomide and R-CHOP reduced the risk of progression or death by 25% in previously untreated high-risk DLBCL. Watch interview👉bit.ly/4cOoYNX #Haematology
279
Join the free ecancer live interactive webinar on telepathology in breast cancer care in LMICs 12:00 BST / 11:00 UTC 25th September. Part of the Grand Rounds in Breast Cancer series. Register👉 ecancer.org/telepathology #BreastCancer #oncology
1
375
At #EHA2026, Prof Anthony Moorman (@UniofNewcastle) discusses UKBlinPredict, using early MRD response and genetic markers such as IKZF1plus and DUX4 rearrangements to predict relapse risk after blinatumomab in B-ALL. Watch the interview 👉 bit.ly/3RWO6ex #ALL
336